 |
|
UBC researcher finds new way to treat devastating fungal infections
March 06, 2007Devastating blood-borne fungal infections that can be lethal for HIV/AIDS, cancer, and organ transplant patients may be treated more successfully, thanks to a new drug delivery method developed by researchers at the University of British Columbia in Vancouver.
Pharmaceutical Sciences Prof. Kishor M. Wasan has created a liquid preparation that incorporates drug molecules in fat (lipid-based formulation) so that Amphotericin B, a potent anti-fungal agent, can be taken by mouth with minimal side effects. The agent, used for about 50 years, is currently administered intravenously and has significant toxic side effects, notably severe kidney toxicity as well as serious tissue damage at the intravenous injection site.
Wasan and his research team have discovered that the oral preparation triggers a different molecular interaction than intravenous delivery. The lipid-based system attacks fungal cells only while inhibiting the drug's interaction with kidney cells - boosting effectiveness and dramatically reducing toxicity.
The research findings will be presented today at a meeting sponsored by the American Association of Pharmaceutical Scientists in Washington, D.C. Findings will be published in July 2007 in Drug Development and Industrial Pharmacy.
Because the oral form of the drug is easier to administer and cheaper than intravenous delivery, Wasan predicts that more patients - especially those in underserved areas and developing countries - would have access to the medicine. He notes that Amphotericin B is also used to treat Leishmaniasis, a parasitic disease that affects an estimated two million people worldwide according to the Centers for Disease Control and Prevention (CDCP) in the U.S.
"This research was triggered by clinicians needing a way to kill these fungal infections without risking the patient's kidney," says Wasan, who is a Distinguished University Scholar and a Canadian Institutes of Health Research Chair in Drug Development. "Despite antifungal agents, treating these infections is difficult and challenges researchers to find better outcomes for the patient."
Wasan tested the drug delivery method, in animal models, against two fungal infections seen in their most severe forms in people with suppressed immune systems, such as surgical patients and those with chronic illness.
He treated Candida albicans, often seen as esophageal candidiasis, an infection prevalent in HIV/AIDS and cancer patients receiving chemotherapy, and aspergillosis, an infection caused by aspergillus fumigatis, a family of common moulds that can cause symptoms ranging from cough to brain damage. The oral formulation proved effective and minimally toxic against both infections.
A clinical study of the drug delivery system, involving 50-100 patients, is planned for later this year. A form of invasive candidiasis called candidemia is the fourth most common bloodstream infection among hospitalized patients in the U.S. A survey conducted at CDCP found that candidemia occurs in eight of every 100,000 persons per year. Persons at high risk include low-birth-weight babies and surgical patients.
Incidence of invasive aspergillosis was five-10 per 1,000, according to an analysis of medical records of 35,232 HIV-infected patients who attended outpatient clinics in 10 U.S. cities between 1990 and 1998, according to Health Canada.
University of British Columbia
The research findings will be presented today at a meeting sponsored by the American Association of Pharmaceutical Scientists in Washington, D.C. Findings will be published in July 2007 in Drug Development and Industrial Pharmacy.
Because the oral form of the drug is easier to administer and cheaper than intravenous delivery, Wasan predicts that more patients - especially those in underserved areas and developing countries - would have access to the medicine. He notes that Amphotericin B is also used to treat Leishmaniasis, a parasitic disease that affects an estimated two million people worldwide according to the Centers for Disease Control and Prevention (CDCP) in the U.S.
"This research was triggered by clinicians needing a way to kill these fungal infections without risking the patient's kidney," says Wasan, who is a Distinguished University Scholar and a Canadian Institutes of Health Research Chair in Drug Development. "Despite antifungal agents, treating these infections is difficult and challenges researchers to find better outcomes for the patient."
Wasan tested the drug delivery method, in animal models, against two fungal infections seen in their most severe forms in people with suppressed immune systems, such as surgical patients and those with chronic illness.
He treated Candida albicans, often seen as esophageal candidiasis, an infection prevalent in HIV/AIDS and cancer patients receiving chemotherapy, and aspergillosis, an infection caused by aspergillus fumigatis, a family of common moulds that can cause symptoms ranging from cough to brain damage. The oral formulation proved effective and minimally toxic against both infections.
A clinical study of the drug delivery system, involving 50-100 patients, is planned for later this year. A form of invasive candidiasis called candidemia is the fourth most common bloodstream infection among hospitalized patients in the U.S. A survey conducted at CDCP found that candidemia occurs in eight of every 100,000 persons per year. Persons at high risk include low-birth-weight babies and surgical patients.
Incidence of invasive aspergillosis was five-10 per 1,000, according to an analysis of medical records of 35,232 HIV-infected patients who attended outpatient clinics in 10 U.S. cities between 1990 and 1998, according to Health Canada.
University of British Columbia
Fungal Infection Current Events and Fungal Infection News RSSWPI Researchers Take Aim at Hard-to-Treat Fungal Infections
A team of researchers at the Worcester Polytechnic Institute (WPI) Life Sciences and Bioengineering Center at Gateway Park has developed a new model system to study fungal infections.
Genetic links to fungal infection risk identified
Two genetic mutations that may put individuals at increased risk of fungal infections have been identified by scientists from UCL and Radboud University, increasing understanding about the genetic basis of these infections and potentially aiding the development of new treatments.
Breast cancer drug shows promise against serious infections
An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer.
Fungi the cause of many outbreaks of disease but mostly ignored
Fungi can cause a number of life-threatening diseases but they also are becoming increasingly useful to science and manufacturing every year.
Predicting the risk of a common fungal infection after stem cell transplantation
In silico genetic analysis in mice has led to the discovery of a gene affecting susceptibility to a severe fungal infection in transplant recipients.
New findings on immune system in amphibians
Krakow/Halle. Major Histocompatibility Complex (MHC) genes produce proteins that are crucial in fighting pathogen assault. Researchers from the Jagiellonian University in Krakow and from the Helmholtz Centre for Environmental Research (UFZ) characterized genetic variation and detected more than one MHC class II locus in a tailed amphibian.
Pregnancy may slow -- not accelerate -- progression to AIDS
A new study may help put to rest fears that pregnancy accelerates progression to full-blown AIDS in women with HIV receiving antiretroviral therapy.
Anti-fungal drug stops blood vessel growth
Researchers at Johns Hopkins have discovered to their surprise that a drug commonly used to treat toenail fungus can also block angiogenesis, the growth of new blood vessels commonly seen in cancers.
Insects cultivate 'antibiotic-producing bacteria' in their antennae
Bacteria live in, on and around us and other organisms with sometimes very beneficial results. For the first time scientists have shown that one species of insect deliberately cultivates bacteria in its antennae in order to protect their larvae from fungal attack.
Infectious disease researchers develop basis for experimental melanoma treatment
While investigating a fungus known to cause an infection in people with AIDS, two grantees of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), unexpectedly discovered a potential strategy for treating metastatic melanoma, one of the deadliest forms of skin cancer.
More Fungal Infection Current Events and Fungal Infection News Articles
 |
Fungal Infection: Diagnosis and Management by Malcolm Richardson (Author), David W. Warnock (Author) Second author, David W. Warnock, is with the Centers for Disease Control and Prevention, Atlanta, GA. Current guide to the clinical manifestations, laboratory diagnosis and management of superficial, subcutaneous, and systemic fungal infections. Previous edition: c1997. For practitioners and residents. Softcover. DNLM: Mycoses--therapy. |
 |
Pocket Guide to Fungal Infection by Malcolm Richardson (Author), Elizabeth Johnson (Author) The Pocket Guide to Fungal Infection presents, in a convenient and practical format, the major features of fungal infections in humans, providing visual information for each pathogen and the infections they cause.
The second edition has been extensively revised. In each chapter the clinical manifestations and management sections have been revised and updated to include recently developed antifungal drugs. New sections include;
Emerging yeast and filamentous fungal pathogens Antifungal susceptibility testing Antifungal assays Molecular methods in medical mycology Mycological aspects of the indoor environment.
Medical... |
 |
Contemporary Diagnosis and Management of Fungal Infections by Jack D. Sobel (Author), MD (Author) The rising incidence of fungal infections, especially among hospitalized patients, makes this handbook a must-read text for clinicians. Expertly organized for quick review, this handbook is written by two outstanding infectious disease specialists. Full-color inserts are included. |
 |
SAPROX Natural Treatment Fungal Skin Infections by Saprox SAPROX is 100% natural clay that contains sulphur and other minerals, humic acids, essential oils and other organic substances that are a product of very slow decomposition of herbs and aquatic plants without presence of oxygen over thousands of years. This natural process preserves beneficial elements within the clay. The combination of all elements play an important part of SAPROX's complex effect. Saprox's significant healing effect is inhibiting and preventing growth of fungus and yeast. The anaerobic condition where Saprox exists prevents parasites, fungus and most bacteria from invading the mud deeming it safe to use on skin without open sores. Do not apply Saprox to an open bleeding skin wound. Saprox may be used on most external fungal skin infections successfully: Tinea... |
 |
Fungal Infections in the Immunocompromised Patient (Infectious Disease and Therapy) by John R. Wingard (Editor), Elias Anaissie (Editor) Unlike any other source on the subject, Fungal Infections in the Immune-Compromised provides an up-to-date account of fungal syndromes in immunocompromised patients and provides expert descriptions of their clinical manifestations and settings in which they cause illness. It covers the pros and cons of current and emerging diagnostic measures, techniques to incorporate new diagnostic tools and treatments into established clinical practices, and the most recent therapeutic strategies in patient care. The book supplies practical tools in the form of algorithms, slides, graphs, figures, photographs, and radiographs to assist in recognition and management of fungal illnesses. |
 |
Clearly Confident Antifungal Cream, 1-Ounce Containers (Pack of 2) by Clearly Confident Nail Advantage NF. Fast acting. See results in 28 days (full care and clearing may require longer usage). Emu Oil patented formulation. Doctor recommended. Apply once daily. Works through nail polish. Ideal for manicurists! Clearly Confident Fungus Treatm |
 |
Ring-Ex - Natural Pet Ringworm Relief - Fungal Skin Infections Treatment (30ml) by Nativeremedies Ringworm may cause various lesions on the skin and these are not always in the shape of a ring. You may notice your pet scratching at areas that look scaly and inflamed and, with time, the hair in these patches may be lost. Ringworm can look very similar to a number of other skin conditions including mange and allergic conditions, so if in doubt it is important to take your pet to a vet in order to be sure of the diagnosis. Usual treatment of ringworm involves use of anti-fungal shampoos or creams. In severe cases oral anti-fungal medication may be used but this has the potential to cause side-effects. PetAlive Ring-Ex contains a blend of natural, herbal ingredients in a medicinal olive oil base, all specially selected to treat ringworm infections. Ring-Ex will also help to prevent the... |
 |
Fungal Infection (Tinea Versicolor) Stay Young for Life (Primary Contributor) |
 |
Atlas of Fungal Infection by Carol A. Kauffman (Editor), Gerald L. Mandell (Editor) This atlas will show the panoply of infections caused by fungi, emphasizing the visual clues to diagnosis of specific fungal diseases. The entire spectrum, from noninvasive cutaneous infections to systemic involvement with the endemic mycoses, to disease from a wide variety of opportunistic pathogens, will be highlighted. |
 |
CELL POWER 1 fl oz. by Positive POWER Nutrition Cellular Oxygenation and Detoxification may be useful for people who suffer from the following conditions: Allergies pH imbalances Emphysema Indigestion Chronic obstructive pulmonary disease (COPD) Kidney infections Chronic fatigue syndrome Skin disorders Bronchial asthma Arthritis and joint pain Short-term memory loss Fibromyalgia Viral, fungal, and bacterial infections Muscle pain 1. A man in Pennsylvania suffering with Leukemia (blood cancer) 4 years, told that all of his options had run out, sent home to die. I personally spoke with this man, named Charles (Chuck). He stated that he was sent home to die in Dec 2006. He didn't feel his time on earth was up, so he started taking several good dietary supplements, including CellPowerTM, and then... |
| © 2009 BrightSurf.com |